Expression and Purification of the Recombinant Kinase Domain of FGFR2b and Study of its Structural Changes Due to the Interaction with Gallic Acid

Document Type : Original Article (s)

Authors

1 Department of Biology, School of Science, Damghan Branch, Islamic Azad University, Damghan, Iran

2 Assistant Professor, Cellular and Molecular Research Center AND Department of Biochemistry and Genetics, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

3 Associate Professor, Department of Biophysics and Biotechnology, School of Paramedical Sciences AND Cellular and Molecular Research Centre, Qazvin University of Medical Sciences, Qazvin, Iran

4 Associate Professor, Cellular and Molecular Research Center AND Department of Biochemistry and Genetics, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

Abstract

Background: FGFR2b plays a significant role in cell signaling pathway, regulating several key biological processes including cellular differentiation and proliferation. Genetic alterations of the tyrosine kinase domain of FGFR2b, such as point mutations, occur in breast, ovarian and prostate cancer. This study aimed to express and zepurify the human FGFR2b kinase domain and to analyze its structural changes upon interaction with Gallic acid (GA).Methods: Expression of recombinant protein was induced with 1mM IPTG at 37 ºC and analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein was purified via affinity chromatography and the protein sample was dialyzed and then used to be analyzed via SDS-PAGE. Chemical denaturation and intrinsic fluorescence spectra of the purified proteins were carried out via adding different concentrations of Gallic acid.Findings: Comparison between pre- and post-induction samples via SDS-PAGE analysis showed that the expressed protein was soluble at 20 ºC. Additionally, its purity was confirmed. The intrinsic fluorescence spectra of kinase domain in the presence of Gallic acid showed an increase in fluorescence intensity and maximum emission wavelength.Conclusion: Regarding to the results, the recombinant kinase domain of FGFR2b (38 kDa) was expressed, solubilized and purified. Changing in tertiary structural kinase domain reflects a conformational change within the protein that is important for the biological function of FGFR2b.

Keywords

References

  1. Matsunaga S, Okigaki M, Takeda M, Matsui A, Honsho S, Katsume A, et al. Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction. J Mol Cell Cardiol 2009; 46(5): 663-73.
  2. Zhao WM, Wang L, Park H, Chhim S, Tanphanich M, Yashiro M, et al. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res 2010; 16(23): 5750-8.
  3. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8(3): 235-53.
  4. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010; 8(11): 1439-52.
  5. Kalinina J, Dutta K, Ilghari D, Beenken A, Goetz R, Eliseenkova AV, et al. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 2012; 20(1): 77-88.
  6. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141(7): 1117-34.
  7. Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 2009; 7(1): 41-54.
  8. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16(2): 179-86.
  9. Jain VK, Turner NC. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res 2012; 14(3): 208.
  10. Lew ED, Bae JH, Rohmann E, Wollnik B, Schlessinger J. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proc Natl Acad Sci USA 2007; 104(50): 19802-7.
  11. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125(1): 105-17.
  12. Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med 2009; 23(3): 307-11.
  13. Katoh M. FGFR2 (fibroblast growth factor receptor 2). Atlas Genet Cytogenet Oncol Haematol 2009; 13(7): 477-82.
  14. Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 2008; 33(2): 233-7.
  15. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26(50): 7158-62.
  16. Lew ED, Furdui CM, Anderson KS, Schlessinger J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal 2009; 2(58): ra6.
  17. Bae JH, Lew ED, Yuzawa S, Tome F, Lax I, Schlessinger J. The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell 2009; 138(3): 514-24.
  18. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di BA, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68(7): 2340-8.
  19. Sorensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005; 115(2): 113-28.
  20. Meinander N, Jeppsson M, Sogaard M. Optimisation of the solubility of the recombinant itk kinase domain in Escherichia coli. In: Merten OW, Mattanovich D, Lang C, Larsson G, Neubauer P, Porro D, et al., editors. Recombinant protein production with prokaryotic and eukaryotic cells. A comparative view on host physiology. New York, NY: Springer; 2001. p. 159-70.
  21. Sambrook JF, Russell DW. Molecular cloning: A laboratory manual. 3rd ed. New York, NY: Cold Spring Harbor Laboratory Press; 2001.
  22. Scheim DE. Cytotoxicity of unsaturated fatty acids in fresh human tumor explants: concentration thresholds and implications for clinical efficacy. Lipids Health Dis 2009; 8: 54.
  23. Gorinstein S, Goshev I, Moncheva S, Zemser M, Weisz M, Caspi A, et al. Intrinsic tryptophan fluorescence of human serum proteins and related conformational changes. J Protein Chem 2000; 19(8): 637-42.
  24. Jana S, Chaudhuri TK, Deb JK. Effects of guanidine hydrochloride on the conformation and enzyme activity of streptomycin adenylyltransferase monitored by circular dichroism and fluorescence spectroscopy. Biochemistry (Mosc ) 2006; 71(11): 1230-7.
  25. Lu Y, Jiang F, Jiang H, Wu K, Zheng X, Cai Y, et al. Gallic acid suppresses cell viability, proliferation, invasion and angiogenesis in human glioma cells. Eur J Pharmacol 2010; 641(2-3): 102-7.
Journal of Isfahan Medical School
Volume 33, Issue 362 - Serial Number 362
November and December 2016
Pages 2143-2151

Files

History

  • Receive Date: 26 August 2015
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics